Specialist pharmaceutical outsourcing services provider, PCI Pharma Services (PCI) has premiered its new contained packaging facility for the primary and secondary packaging of highly potent products at its newly acquired site near Dublin, Ireland.
According to PCI, the company is the recognised global leader in the manufacturing of highly potent molecules at its purpose-built contained manufacturing facility at its Tredegar site in Wales, UK.
This latest investment in contained packaging capabilities at the PCI Ireland site ensures PCI’s ongoing commitment to delivering the highest standards of safety and regulatory adherence for specialised medicines. It is also the most recent part of PCI’s strategic initiative to develop its high containment operations (HCO) services globally.
“We are very excited to officially launch our state-of-the-art high contained packaging facility here in Ireland,” said Bill Mitchell, President and CEO.
“The Republic of Ireland has a thriving pharmaceutical and biotech community which PCI has been fortunate to support for many years. We have already received a tremendous response to the acquisition and investments such as this high containment packaging facility are part of our strategic plan to continue business growth and service development for our customers. PCI is proud to provide services for medicines destined to more than 100 countries around the world and the Dublin site itself to more than 50 countries.”
After the acquisition of Millmount Healthcare, PCI has added approximately 30 positions at the Dublin area facilities and anticipates adding more than 100 positions in the next five years as the sites continue to expand and grow its operations.
